Literature DB >> 27113251

Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib.

Benoit Branco1, David Metsu2,3, Marine Dutertre4,5, Bruno Marchou4,5, Pierre Delobel4,5, Christian Recher1,5, Guillaume Martin-Blondel6,7,8,9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27113251     DOI： 10.1007/s00277-016-2684-0

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  8 in total

Review 1.  Fatal Disseminated Tuberculosis and Concurrent Disseminated Cryptococcosis in a Ruxolitinib-treated Patient with Primary Myelofibrosis: A Case Report and Literature Review.

Authors:  Asuka Ogai; Kazuma Yagi; Fumimaro Ito; Hideharu Domoto; Tetsuya Shiomi; Kenko Chin
Journal:  Intern Med       Date:  2021-09-25       Impact factor: 1.282

2.  Tuberculosis in Patients with Primary Myelofibrosis During Ruxolitinib Therapy: Case Series and Literature Review.

Authors:  Yizhou Peng; Li Meng; Xuemei Hu; Zhiqiang Han; Zhenya Hong
Journal:  Infect Drug Resist       Date:  2020-09-28       Impact factor: 4.003

3.  Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis.

Authors:  Douglas Tremblay; Amber King; Lihua Li; Erin Moshier; Alexander Coltoff; Anita Koshy; Marina Kremyanskaya; Ronald Hoffman; Michael J Mauro; Raajit K Rampal; John Mascarenhas
Journal:  Leuk Lymphoma       Date:  2019-11-12

4.  Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib.

Authors:  Maheen Z Abidi; Javeria Haque; Parvathi Varma; Horatiu Olteanu; Guru Subramanian Guru Murthy; Binod Dhakal; Parameswaran Hari
Journal:  Case Rep Hematol       Date:  2016-10-23

5.  Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor.

Authors:  Palma Manduzio
Journal:  Ther Clin Risk Manag       Date:  2017-02-13       Impact factor: 2.423

Review 6.  Fatal Disseminated Tuberculosis during Treatment with Ruxolitinib Plus Prednisolone in a Patient with Primary Myelofibrosis: A Case Report and Review of the Literature.

Authors:  Yasuhiro Tsukamoto; Junichi Kiyasu; Mariko Tsuda; Motohiko Ikeda; Motoaki Shiratsuchi; Yoshihiro Ogawa; Yuji Yufu
Journal:  Intern Med       Date:  2017-12-27       Impact factor: 1.271

Review 7.  Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL).

Authors:  Georg Maschmeyer; Julien De Greef; Sibylle C Mellinghoff; Annamaria Nosari; Anne Thiebaut-Bertrand; Anne Bergeron; Tomas Franquet; Nicole M A Blijlevens; Johan A Maertens
Journal:  Leukemia       Date:  2019-01-30       Impact factor: 11.528

8.  Prediction of potential drug interactions between repurposed COVID-19 and antitubercular drugs: an integrational approach of drug information software and computational techniques data.

Authors:  Levin Thomas; Sumit Raosaheb Birangal; Rajdeep Ray; Sonal Sekhar Miraj; Murali Munisamy; Muralidhar Varma; Chidananda Sanju S V; Mithu Banerjee; Gautham G Shenoy; Mahadev Rao
Journal:  Ther Adv Drug Saf       Date:  2021-08-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.